Galit Meshulam-Simon is the associate director of Commercial Applications at Elegen. COVID-19 brought messenger RNA (mRNA) into the global spotlight, demonstrating its speed, flexibility, and efficacy ...

A team of researchers has uncovered a key cellular mechanism that affects the function of mRNA vaccines and therapeutics. Their study provides the first comprehensive understanding of how mRNA ...

Ongoing federal support for mRNA technology and research could make good on a longstanding presidential promise to cure cancer, according to Jeff Coller, Bloomberg Distinguished Professor of RNA ...

Moderna MRNA announced that the Coalition for Epidemic Preparedness Innovations (“CEPI”) will invest up to $54.3 million in funding to support a pivotal phase III study evaluating its investigational ...

The U.S. Department of Health and Human Services (HHS) recently announced it will wind down funding for mRNA vaccine development—which could prove to be one of the costliest, deadliest decisions HHS ...